In a pilot phase 1 study, the DNA vaccine encoding a full-length signaling-deficient version of HER2 was injected together with GM-CSF and IL-2 to 8 patients with metastatic HER2-positive breast cancer who were also treated by trastuzumab (97). The gene discussed is CSF2; the disease is breast cancer.